Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nutex Health (NUTX) Total Liabilities (2016 - 2025)

Nutex Health's Total Liabilities history spans 16 years, with the latest figure at $495.1 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 9.19% year-over-year to $495.1 million; the TTM value through Dec 2025 reached $495.1 million, up 9.19%, while the annual FY2025 figure was $495.1 million, 9.19% up from the prior year.
  • Total Liabilities for Q4 2025 was $495.1 million at Nutex Health, down from $526.5 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $526.5 million in Q3 2025 and bottomed at $5.4 million in Q1 2023.
  • The 5-year median for Total Liabilities is $321.7 million (2023), against an average of $272.2 million.
  • The largest annual shift saw Total Liabilities soared 15476.94% in 2021 before it plummeted 47.17% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $203.1 million in 2021, then surged by 53.36% to $311.4 million in 2022, then grew by 2.48% to $319.1 million in 2023, then soared by 42.08% to $453.4 million in 2024, then increased by 9.19% to $495.1 million in 2025.
  • Per Business Quant, the three most recent readings for NUTX's Total Liabilities are $495.1 million (Q4 2025), $526.5 million (Q3 2025), and $504.2 million (Q2 2025).